Avanir Pharmaceuticals, Inc. (AVNR - Snapshot Report) reported that results from a pharmacokinetic (PK) study of AVP-825 were published in the journal, Headache. AVP-825 is being developed using OptiNose's novel Breath Powered intranasal delivery system, which includes low dosages of GlaxoSmithKline plc’s (GSK - Analyst Report) Imitrex (sumatriptan) for the treatment of acute migraine.
The randomized, pharmacokinetic study evaluated the pharmacokinetics of AVP-825 and compared it with the pharmacokinetics of three other sumatriptan products: 20 mg liquid nasal spray, 100 mg oral tablet and 6 mg subcutaneous injection.
Data showed that AVP-825 is highly efficient for delivering sumatriptan with a higher peak exposure (27%), and greater early exposure (75%) in the crucial first 15 minutes after treatment than liquid nasal spray, despite the AVP-825 dose being lower (16 mg). The study also revealed that AVP-825 gave greater overall intranasal delivery efficiency, with the average total drug exposure per milligram being one third higher than the total exposure per milligram achieved with the liquid nasal spray.
Overall, AVP-825 has advantages over other sumatriptan products currently available to treat migraine as it produces rapid and efficient medication absorption.
As per the Centers for Disease Control and Prevention, more than 37 million Americans suffer from migraine headaches.
In Jul 2013, Avanir joined forces with OptiNose for the development and commercialization of AVP-825 for the treatment of acute migraine. Once approved, it will be the first and only fast-acting, dry-powder nasal delivery form of Imitrex.
Avanir currently carries a Zacks Rank #3 (Hold). Companies that look well-positioned include Questcor Pharmaceuticals Inc. and Actelion Ltd. (ALIOF), both ofwhich carry a Zacks Rank #1 (Strong Buy).